366 related articles for article (PubMed ID: 1765894)
1. Human T-cell lymphotrophic virus in California's injection drug users.
Trachtenberg AI; Gaudino JA; Hanson CV
J Psychoactive Drugs; 1991; 23(2):225-32. PubMed ID: 1765894
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of HTLV-I and HTLV-II infection in the AIDS epidemic.
Pierik LT; Murphy EL
AIDS Clin Rev; 1991; ():39-57. PubMed ID: 1868010
[TBL] [Abstract][Full Text] [Related]
3. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.
de la Fuente L; Toro C; Soriano V; Brugal MT; Vallejo F; Barrio G; Jiménez V; Silva T;
J Clin Virol; 2006 Mar; 35(3):244-9. PubMed ID: 16143565
[TBL] [Abstract][Full Text] [Related]
4. Human T lymphotropic virus type I/II infection: prevalence and risk factors in individuals testing for HIV in counseling centers from Southern Brazil.
Barcellos NT; Fuchs SC; Mondini LG; Murphy EL
Sex Transm Dis; 2006 May; 33(5):302-6. PubMed ID: 16505751
[TBL] [Abstract][Full Text] [Related]
5. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression.
Casoli C; Pilotti E; Bertazzoni U
AIDS Rev; 2007; 9(3):140-9. PubMed ID: 17982939
[TBL] [Abstract][Full Text] [Related]
6. Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe.
Jõgeda EL; Avi R; Pauskar M; Kallas E; Karki T; Des Jarlais D; Uusküla A; Lutsar I; Huik K
Infect Genet Evol; 2016 Sep; 43():83-5. PubMed ID: 27223634
[TBL] [Abstract][Full Text] [Related]
7. Absence of human T cell lymphotrophic virus (HTLV) type I and II DNA in French anti-HTLV-I/II-negative intravenous drug users.
Lefrère F; Wattel E; Mariotti M; Agis F; Gordien E; Lefrère JJ
J Infect Dis; 1992 Jul; 166(1):212-3. PubMed ID: 1607702
[No Abstract] [Full Text] [Related]
8. Determination of the true prevalence of infection with the human T-cell lymphotropic viruses (HTLV-I/II) may require a combination of biomolecular and serological analyses.
Pancake BA; Zucker-Franklin D; Marmor M; Legler PM
Proc Assoc Am Physicians; 1996 Nov; 108(6):444-8. PubMed ID: 8956367
[TBL] [Abstract][Full Text] [Related]
9. The epidemiology and disease outcomes of human T-lymphotropic virus type II.
Roucoux DF; Murphy EL
AIDS Rev; 2004; 6(3):144-54. PubMed ID: 15595431
[TBL] [Abstract][Full Text] [Related]
10. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
Blejer JL; Saguier MC; Salamone HJ; Carreras LA
Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of HTLV-I/II and HIV-1 among intravenous drug users in Detroit.
Ognjan AF; Lewandowski CA; Belian BT; Burczak J; Markowitz N; Lee H; Saravolatz LD
Henry Ford Hosp Med J; 1992; 40(1-2):131-5. PubMed ID: 1428966
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia.
Prasetyo AA; Dirgahayu P; Sari Y; Hudiyono H; Kageyama S
J Infect Dev Ctries; 2013 Jun; 7(6):453-67. PubMed ID: 23771289
[TBL] [Abstract][Full Text] [Related]
13. Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: an old infection?
Khabbaz RF; Hartel D; Lairmore M; Horsburgh CR; Schoenbaum EE; Roberts B; Hartley TM; Friedland G
J Infect Dis; 1991 Feb; 163(2):252-6. PubMed ID: 1988509
[TBL] [Abstract][Full Text] [Related]
14. Seroepidemiology of viral infections among intravenous drug users in northern California.
Zeldis JB; Jain S; Kuramoto IK; Richards C; Sazama K; Samuels S; Holland PV; Flynn N
West J Med; 1992 Jan; 156(1):30-5. PubMed ID: 1310362
[TBL] [Abstract][Full Text] [Related]
15. Seroepidemiology and clinical aspects of human T-cell lymphotropic virus type I/II infection in a cohort of intravenous drug users in New York City.
Brown LS; Chu A; Allain JP; Lee H; Cerney M; Nemoto T
N Y State J Med; 1991 Mar; 91(3):93-7. PubMed ID: 2047026
[TBL] [Abstract][Full Text] [Related]
16. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression.
Brites C; Sampalo J; Oliveira A
AIDS Rev; 2009; 11(1):8-16. PubMed ID: 19290030
[TBL] [Abstract][Full Text] [Related]
17. HTLV-1/2 among high-risk groups in Argentina: molecular diagnosis and prevalence of different sexual transmitted infections.
Berini CA; Pando MA; Bautista CT; Eirin ME; Martinez-Peralta L; Weissenbacher M; Avila MM; Biglione MM
J Med Virol; 2007 Dec; 79(12):1914-20. PubMed ID: 17935172
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of human T-cell lymphotropic virus type 1 and 2 among patients with malignant hematological diseases in south Chile.
Barrientos A; Lopez M; Sotomayor C; Pilleux L; Calderón S; Navarrete M; Otth C
J Med Virol; 2011 Apr; 83(4):745-8. PubMed ID: 21328393
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of HIV-1, HIV-2 and HTLV antibody, in Fortaleza, Ceara, Brazil, 1993-1994.
Broutet N; de Queiroz Sousa A; Basilio FP; Sá HL; Simon F; Dabis F
Int J STD AIDS; 1996; 7(5):365-9. PubMed ID: 8894828
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases.
Giuliani M; Rezza G; Lepri AC; Di Carlo A; Maini A; Crescimbeni E; Palamara G; Prignano G; Caprilli F
Sex Transm Dis; 2000 Feb; 27(2):87-92. PubMed ID: 10676975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
